AveXis, Inc., a clinical -
stage gene therapy company developing
treatments for patients suffering from rare and life - threatening neurological genetic diseases, announced in July 2016 that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the
treatment based on
preliminary clinical results from the trial
of AVXS - 101.